Brand-Name Drug Makers Win Key Provisions In Central American Free-Trade Pact
U.S. brand-name drug makers appear to have scored a major victory with the pharmaceutical provisions of the Central American Free Trade Agreement, which would provide five years of market exclusivity to...To view the full article, register now.
Already a subscriber? Click here to view full article